Oxford-based Brainomix has secured £14M in Series C funding to expand its AI-powered imaging solutions for stroke and lung fibrosis. The investment comes from a mix of existing and new investors, including Parkwalk Advisors, Boehringer Ingelheim Venture Fund, and Hostplus via the IP Group Hostplus Innovation Fund. Brainomix aims to use these funds to strengthen its presence in the US and enhance its AI-driven diagnostic tools. The company has seen growing adoption of its technology, which has been integrated into numerous hospitals globally, supporting patient care through advanced imaging analysis.
Brainomix has previously raised significant funding rounds, with a focus on improving stroke care through AI. The company’s earlier investments supported the development of Brainomix 360 Stroke, an AI-powered imaging platform that assists clinicians in diagnosing and treating strokes. Over time, the company has expanded its AI applications into lung disease, particularly lung fibrosis, which is a progressive and often difficult-to-diagnose condition. The latest funding round follows a series of regulatory approvals, including FDA clearance, positioning the company for broader international expansion.
How does Brainomix’s AI technology impact stroke and lung disease care?
The Brainomix 360 Stroke platform is designed to analyze medical images rapidly, allowing for more efficient stroke diagnosis and treatment decisions. Studies indicate that its implementation has contributed to a 50% increase in mechanical thrombectomy procedures, a treatment that can significantly improve patient outcomes. Brainomix has expanded beyond stroke imaging by developing Brainomix 360 e-Lung, an AI-powered tool that predicts lung fibrosis progression, which has received regulatory approval in the US.
The company is working with Boehringer Ingelheim, a pharmaceutical firm specializing in lung fibrosis treatments, to explore how AI-based imaging can enhance diagnosis and accessibility to treatments. The collaboration seeks to improve patient management by integrating AI into routine clinical workflows. These technological advancements aim to make early and accurate diagnosis more accessible to healthcare providers and patients.
What are the company’s next steps following the investment?
Brainomix plans to use the new funding to expand its operations in the US, where it has received multiple FDA clearances. The investment will also support ongoing research and development efforts to refine its AI imaging tools. The company has stated that it will focus on increasing commercial adoption of its technology in hospitals and healthcare institutions worldwide.
Brainomix CEO Dr. Michalis Papadakis expressed appreciation for the investor support, emphasizing the company’s commitment to delivering AI solutions for stroke and lung fibrosis care.
“We would like to thank all the investors that participated, including Parkwalk and Boehringer Ingelheim Venture Fund for their continued support, and welcome Hostplus, all of whom recognise the transformative impact that our technology can have on treatment for stroke and lung fibrosis patients.”
He further emphasized the company’s goal of expanding its influence in the US market.
UK Minister of State for Science, Research and Innovation, Lord Patrick Vallance, highlighted the significance of Brainomix’s AI solutions in healthcare.
“The AI tools developed by Brainomix are already helping patients get fast and accurate diagnosis and treatment for a range of serious conditions. Securing this funding will help them to grow, create more jobs, and support more patients.”
He also noted that investments in such technologies contribute to the UK’s broader economic and research growth.
Brainomix has positioned itself as a key player in AI-driven medical imaging, with its technology already assisting over 1.5 million patients across more than 300 hospitals. Its approvals from NICE and the FDA reinforce the credibility of its AI solutions in clinical use. However, the company faces competition from other AI-driven medical imaging firms, each striving to enhance diagnostic accuracy and efficiency.
As AI continues to be integrated into medical diagnostics, Brainomix’s focus on expanding its reach and refining its technology will be critical. While its solutions have demonstrated effectiveness in improving stroke and lung fibrosis diagnosis, broader adoption will depend on policy support, regulatory compliance, and continued validation through clinical data. The increasing investment in AI healthcare technologies underscores the sector’s potential to support faster diagnoses and more personalized patient treatments.
